Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

R&D expense for the third quarter of 2024 was $7.2 million, compared to $7.3 million for the third quarter of 2023. The decrease of $0.1 million was primarily due to lower clinical trial expenses ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Ed Schuuring, Senior Clinical Scientist in Molecular Pathology and Professor of Molecular Oncology in the Department of ...

New results from a pooled analysis of patients will be featured in a late-breaking presentation at the upcoming European ...

"Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes, which makes it hard to study in large clinical trials," said lead author Yvonne Mowery, M.D., Ph.D., associate ...